Glycoconjugation processes and compositions
The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
1. A method of preventing, treating or ameliorating a bacterial infection, disease or condition in a subject, comprising administering to the subject an immunologically effective amount of an immunogenic glycoconjugate composition comprising a bacterial capsular polysaccharide conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, wherein the polysaccharide is covalently linked to the eTEC spacer through a carbamate linkage, and wherein the carrier protein is covalently linked to the eTEC spacer through an amide linkage.
2. The method of claim 1 , wherein the bacterial capsular polysaccharide is derived from S. pneumoniae.
3. The method of claim 1 , wherein the infection, disease or condition is associated with S. pneumoniae bacteria.
4. The method of claim 2 , wherein the bacterial capsular polysaccharide is selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides.
5. The method of claim 1 , wherein the bacterial capsular polysaccharide is derived from N. meningitidis.
6. The method of claim 1 , wherein the infection, disease or condition is associated with N. meningitidis bacteria.
7. The method of claim 5 , wherein the bacterial capsular polysaccharide is selected from the group consisting of Mn-serotype A, C, W135, and capsular polysaccharides.
8. The method of claim 1 , wherein the carrier protein is CRM 197 .
9. A method of inducing a protective immune response in a subject, comprising administering to the subject an immunologically effective amount of an immunogenic composition comprising a bacterial capsular polysaccharide conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, wherein the polysaccharide is covalently linked to the eTEC spacer through a carbamate linkage, and wherein the carrier protein is covalently linked to the eTEC spacer through an amide linkage.
10. The method of claim 9 , wherein the bacterial capsular polysaccharide is derived from S. pneumoniae.
11. The method of claim 9 , wherein the infection, disease or condition is associated with S. pneumoniae bacteria.
12. The method of claim 10 , wherein the bacterial capsular polysaccharide is selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides.
13. The method of claim 9 , wherein the bacterial capsular polysaccharide is derived from N. meningitidis.
14. The method of claim 9 , wherein the infection, disease or condition is associated with N. meningitidis bacteria.
15. The method of claim 13 , wherein the bacterial capsular polysaccharide is selected from the group consisting of Mn-serotype A, C, W135, and capsular polysaccharides.
16. The method of claim 9 , wherein the carrier protein is CRM 197 .